Redx Pharma plc Result of Annual General Meeting (9334S)
14 March 2023 - 10:45PM
UK Regulatory
TIDMREDX
RNS Number : 9334S
Redx Pharma plc
14 March 2023
REDX PHARMA PLC
("Redx" or "the Company")
Result of Annual General Meeting
Alderley Park, UK, 14 March 2023 Redx (AIM:REDX), the
clinical-stage biotechnology company focused on discovering and
developing novel, small molecule, highly targeted therapeutics for
the treatment of cancer and fibrotic disease announces that its
Annual General Meeting was held at 11am on 14 March 2023, with all
resolutions passed by substantial majorities.
The table below sets out the details of the votes put to
shareholders
Resolution Resolution Number % of votes Number % of % of Total
number name of votes for & of votes votes votes votes
for & discretionary against against withheld* cast (including
discretionary withheld)
Receive the
Company's
1 annual accounts 306,243,523 94.91% 16,434,331 5.09% 0.00% 322,680,605
---------------- ---------------- ---------------- ----------- -------- ---------- ----------------
Re-appoint
Ernst & Young
2 as auditors 322,677,854 100.00% 2,751 0.00% 0.00% 322,680,605
---------------- ---------------- ---------------- ----------- -------- ---------- ----------------
Re-elect
Dr Bernhard
Kirschbaum
3 as a director 306,241,648 94.91% 16,436,206 5.09% 0.00% 322,680,605
---------------- ---------------- ---------------- ----------- -------- ---------- ----------------
Re-elect
Lisa Anson
4 as a director 322,678,730 100.00% 1,875 0.00% 0.00% 322,680,605
---------------- ---------------- ---------------- ----------- -------- ---------- ----------------
Re-elect
Natalie Berner
5 as a director 322,673,730 100.00% 6,875 0.00% 0.00% 322,680,605
---------------- ---------------- ---------------- ----------- -------- ---------- ----------------
Authorise
the directors
to allot
6 shares 322,551,347 99.96% 125,732 0.04% 0.00% 322,680,605
---------------- ---------------- ---------------- ----------- -------- ---------- ----------------
Disapply
pre-emption
7 rights 322,545,847 99.96% 133,983 0.04% 0.00% 322,680,605
---------------- ---------------- ---------------- ----------- -------- ---------- ----------------
*A vote withheld is not a vote in law and is not counted in the
calculation of the proportion of votes 'For' or 'Against'
For further information, please
contact:
Redx Pharma Plc T: +44 (0)1625 469918
UK Headquarters
Caitlin Pearson, Head of Communications
ir@redxpharma.com
Lisa Anson, Chief Executive Officer
US Office
Peter Collum, Chief Financial Officer
SPARK Advisory Partners (Nominated Adviser) T: +44 (0)203 368
3550
Matt Davis/ Adam Dawes
WG Partners LLP (Joint Broker) T: +44 (0)203 705
9330
Claes Spång/ Satheesh Nadarajah/
David Wilson
Panmure Gordon (UK) Limited (Joint Broker) T: +44 (0)207 886
2500
Rupert Dearden/ Freddy Crossley/ Emma
Earl
FTI Consulting T: +44 (0)203 727
1000
Simon Conway/ Ciara Martin
About Redx Pharma Plc
Redx Pharma (AIM: REDX) is a clinical-stage biotechnology
company focused on the discovery and development of novel, small
molecule, highly targeted therapeutics for the treatment of cancer
and fibrotic disease and the emerging area of cancer-associated
fibrosis, aiming initially to progress them to clinical proof of
concept before evaluating options for further development and
potential value creation. The Company's lead fibrosis product
candidate, the selective ROCK2 inhibitor RXC007, is in development
for interstitial lung disease and commenced a Phase 2a trial for
idiopathic pulmonary fibrosis (IPF) in October 2022, with topline
data expected in Q1 2024. Redx's lead oncology product candidate,
the Porcupine inhibitor RXC004, being developed as a targeted
treatment for Wnt-ligand dependent cancers, is expected to report
both monotherapy and combination with anti-PD-1 Phase 2 data during
2023. Redx's third drug candidate, RXC008, a GI-targeted ROCK
inhibitor for the treatment of fibrostenotic Crohn's disease, is
progressing towards a CTA/IND application at the end of 2023.
The Company has a strong track record of discovering new drug
candidates through its core strengths in medicinal chemistry and
translational science, enabling the Company to discover and develop
differentiated therapeutics against biologically or clinically
validated targets. The Company's accomplishments are evidenced not
only by its two wholly-owned clinical-stage product candidates and
rapidly expanding pipeline, but also by its strategic transactions,
including the sale of pirtobrutinib (RXC005, LOXO-305), a
non-covalent (reversible) BTK inhibitor now approved by the US FDA
for adult patients with mantle cell lymphoma previously treated
with a covalent BTK inhibitor, and AZD5055/RXC006, a Porcupine
inhibitor targeting fibrotic diseases including IPF, which
AstraZeneca is progressing in a Phase 1 clinical study. In
addition, Redx has forged collaborations with Jazz Pharmaceuticals,
which includes JZP815, a pan-RAF inhibitor developed by Redx which
Jazz is now progressing through Phase 1 clinical studies, and an
early stage oncology research collaboration.
To subscribe to Email Alerts from Redx, please visit:
www.redxpharma.com/investor-centre/email-alerts/
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
RAGDZGMFMDMGFZM
(END) Dow Jones Newswires
March 14, 2023 07:45 ET (11:45 GMT)
Redx Pharma (LSE:REDX)
Historical Stock Chart
From Nov 2024 to Dec 2024
Redx Pharma (LSE:REDX)
Historical Stock Chart
From Dec 2023 to Dec 2024
